Inhalable Biologics Market Report 2026

The inhalable biologics market size has grown rapidly in recent years. It will grow from $3.22 billion in 2025 to $3.73 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, limitations of injectable biologics, advances in inhalation device technology, growing biologics pipeline, increasing hospital-based respiratory care.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $6.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to growth in chronic respiratory disorders, expansion of inhalable biologics beyond respiratory indications, increasing patient preference for non-invasive therapies, advancements in formulation stability, rising investments in pulmonary drug delivery research. Major trends in the forecast period include expansion of pulmonary delivery for systemic biologics, growing use of dry powder inhalers for biologics, rising focus on targeted lung drug delivery, increasing development of inhalable monoclonal antibodies, adoption of patient-friendly non-invasive biologic therapies.

The rising prevalence of respiratory conditions is expected to drive the growth of the inhalable biologics market in the coming years. Respiratory conditions encompass diseases and disorders that affect the lungs and other components of the respiratory system, including the airways and nasal passages. The growing occurrence of these conditions is largely attributed to increasing air pollution, which worsens illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics offer advantages for treating respiratory conditions by delivering targeted therapies directly to the lungs, helping to reduce inflammation and enhance lung function while minimizing systemic side effects. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden in 2023. Consequently, the increasing incidence of respiratory conditions is a significant factor driving the expansion of the inhalable biologics market.

Major companies operating in the inhalable biologics market are emphasizing the development of innovative solutions, such as inhaled insulin, to enhance patient adherence and enable rapid glycemic control. Inhaled insulin is an insulin formulation administered through the lungs via inhalation rather than by injections or insulin pumps. This approach involves inhaling a powdered or aerosolized form of insulin, which is absorbed through the pulmonary system and rapidly enters the bloodstream to regulate blood glucose levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, obtained regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, providing a groundbreaking, needle-free treatment option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin begins working within 12 to 15 minutes after inhalation, closely replicating the body’s natural insulin response to meals and supporting improved blood sugar management. Inhaled insulin also offers a more convenient alternative to multiple daily injections, particularly benefiting individuals with injection-related anxiety and improving adherence to insulin therapy.

In October 2025, Merck & Co., Inc., a US-based provider of pharmaceuticals, vaccines, and cardiopulmonary therapies, acquired Verona Pharma for $10 billion. Through this acquisition, Merck sought to strengthen and diversify its cardiopulmonary and respiratory portfolio by adding a novel inhaled therapy. Verona Pharma is a UK-based biopharmaceutical company focused on respiratory diseases, with its primary product being Ohtuvayre (ensifentrine), a first-in-class inhaled dual PDE3/4 inhibitor for the treatment of COPD.

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‑La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the inhalable biologics market by increasing costs for imported biologic raw materials, inhalation devices, and precision manufacturing equipment, affecting overall production economics. These impacts are most evident in dry powder inhalers and nebulizer-based biologic formulations, particularly across Asia-Pacific and Europe where device manufacturing and biologic sourcing are concentrated. Higher tariffs have contributed to pricing pressure in hospital and retail pharmacy channels. However, tariffs have also encouraged regional manufacturing, localized device sourcing, and innovation in cost-efficient inhalable biologic production.

The inhalable biologics market research report is one of a series of new reports that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with a inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inhalable biologics are biologic drugs delivered through the respiratory tract via inhalation. This route of administration enables targeted treatment of lung conditions or systemic therapy by directly reaching the lungs, improving drug efficacy, and minimizing side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive compounds developed to regulate specific cellular pathways or to replace missing or deficient proteins. These therapeutics are available in multiple dosage forms, such as dry powder inhalers, metered dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.